What others say: Trump’s talk on lower drug prices fails to materialize

  • Sunday, July 22, 2018 12:12am
  • Opinion

It has been two months since the president released his road map for lowering drug costs that seems to lead nowhere, and about a month since he predicted the “big drug companies” would announce “voluntary massive” price cuts. Here’s where things stand:

A congressional investigation has found that the drug company Novartis got more out of its $1.2 million payment to Mr. Trump’s “personal attorney” Michael Cohen than had been known. Meanwhile, several other drugmakers defied Mr. Trump’s lofty prediction by raising their prices substantially, while his administration shot down a proposal that would have helped individual states lower their drug costs.

Taken together, the developments help explain why, a year and a half after Mr. Trump took office, prescription drugs cost more than ever.

Let’s start with Novartis: When a lawyer for Stephanie Clifford, the pornographic-film star suing Mr. Trump, revealed that the drug company was among those who had made payments to Mr. Cohen after the election, Novartis executives insisted they’d had only one meeting before concluding that Mr. Cohen didn’t know enough about health care policy to be helpful. But Senate Democrats have since found that the company actually had several meetings, that drug-pricing policies were on the agenda and that a number of proposals Novartis pushed for made it into the White House plan.

For his part, Mr. Trump made a show of chastising the industry on Twitter when several drugmakers raised their prices this month. He called out Pfizer specifically, saying the company “should be ashamed” of itself. The tweet led to a phone call between the company’s chief executive and the president, after which Pfizer agreed to hold off on those price increases for six months, or until the administration had a chance to put its road map into action.

Mr. Trump said the concession was “great news for the American people,” but it might actually be more of a coup for the pharmaceutical industry. By tying its actions to the president’s initiative, Pfizer now has both a stick and a carrot to wield: implement a policy that benefits the industry and maybe the company will abandon its price increases; create one that hurts the industry and the company may raise prices once again. In any case, none of the other drugmakers that raised their prices followed Pfizer’s lead, meaning that those increases are all still in place.

These machinations would be troubling enough by themselves. But the administration seems intent on adding insult to injury, by blocking states from carrying out a policy that might actually make a dent in the drug-cost problem.

That proposal would have opened the door on allowing state Medicaid programs to deny coverage for certain medications. Private insurance companies, the Department of Veterans Affairs and many other countries with drug prices far lower than ours already do this, but Medicaid is required to cover all federally approved medications, no matter how much they cost or how well (or poorly) they work. If states were allowed to circumvent this rule, they would be able to avoid paying for pricey new drugs that aren’t necessarily as effective as cheaper versions already on the market. They would also have much more negotiating power because they would be able to walk away from the table for drugs that were overpriced.

Massachusetts asked the administration for a waiver that would allow it to try this approach. But in June, the Centers for Medicare and Medicaid Services, the Health and Human Services agency that regulates these two insurance programs, rejected that proposal and issued a notice to all states, reiterating that all Medicaid programs must cover all drugs.

“It takes away a substantial tool that a lot of states were hoping to use,” says Rachel Sachs, a law professor and drug policy expert at Washington University in St. Louis. It also points to a hypocrisy, she says. “They’re permissive when it comes to work requirements that put added burden on the vulnerable, but protective when it comes to measures that would strain the pharmaceutical industry.”

It’s unclear where we go from here. The administration’s road map for lowering drug costs was short on details about when or how any of its provisions might take effect. And while there’s no telling what Mr. Trump discussed with Pfizer that caused it to temporarily halt planned price increases, the exchanges between Mr. Cohen and Novartis hardly inspire good faith. In fact, if the industry is “getting away with murder,” as Mr. Trump once claimed, it stands to reason that at this point, it’s doing it with the president’s help.

The good news is that elections are coming, and lawmakers know that Americans are enraged by soaring drug costs. By keeping the pressure on, we may see real change yet.

—The New York Times, July 17, 2018

More in Opinion

A silver salmon is weighed at Three Bears in Kenai, Alaska. Evelyn McCoy, customer service PIC at Three Bears, looks on. (Photo by Jeff Helminiak/Peninsula Clarion)
Opinion: Will coho salmon be the next to disappear in the Kenai River?

Did we not learn anything from the disappearance of the kings from the Kenai River?

Jonathan Flora is a lifelong commercial fisherman and dockworker from Homer, Alaska.
Point of View: Not fishing for favors — Alaskans need basic health care access

We ask our elected officials to oppose this bill that puts our health and livelihoods in danger.

Alex Koplin. (courtesy photo)
Opinion: Public schools do much more than just teach the three Rs

Isn’t it worth spending the money to provide a quality education for each student that enters our schools?

Gov. Mike Dunleavy speaks to reporters at the Alaska State Capitol on Thursday, April 17, 2025. (Jasz Garrett / Juneau Empire file photo)
Letter to the Editor: Law enforcement officers helped ensure smooth, secure energy conference

Their visible commitment to public safety allowed attendees to focus fully on collaboration, learning, and the important conversations shaping our path forward.

Laurie Craig / Juneau Empire file photo
The present-day KTOO public broadcasting building, built in 1959 for the U.S. Army’s Alaska Communications System Signal Corps, is located on filled tidelands near Juneau’s subport. Today vehicles on Egan Drive pass by the concrete structure with satellite dishes on the roof that receive signals from NPR, PBS and other sources.
My Turn: Stand for the community radio, not culture war optics

Alaskans are different and we pride ourselves on that. If my vehicle… Continue reading

U.S. Sen. Dan Sullivan (R-Alaska) delivers his annual speech to the Alaska Legislature on Thursday, March 20, 2025. (Jasz Garrett / Juneau Empire file photo)
Opinion: Sullivan, Trump and the rule of lawlessness

In September 2023, U.S. Sen. Dan Sullivan established his own Alaska Federal… Continue reading

UAA Provost Denise Runge photographed outside the Administration and Humanities Building at the University of Alaskas Anchorage. (courtesy photo)
Opinion: UAA’s College of Health — Empowering Alaska’s future, one nurse at a time

At the University of Alaska Anchorage, we understand the health of our… Continue reading

U.S. Rep. Nick Begich III, R-Alaska, address a joint session of the Alaska Legislature on Thursday, Feb. 20, 2025. (Mark Sabbatini / Juneau Empire file photo)
Opinion: A noncongressman for Alaska?

It’s right to ask whether Nick Begich is a noncongressman for Alaska.… Continue reading

Boats return to the Homer Harbor at the end of the fishing period for the 30th annual Winter King Salmon Tournament on Saturday, March 23, 2024 in Homer, Alaska. (Delcenia Cosman/Homer News)
Opinion: Funding sustainable fisheries

Spring is always a busy season for Alaska’s fishermen and fishing communities.… Continue reading

Gov. Mike Dunleavy holds a press conference on Monday, May 19, 2025, to discuss his decision to veto an education bill. (Jasz Garrett / Juneau Empire file photo)
Opinion: On fiscal policy, Dunleavy is a governor in name only

His fiscal credibility is so close to zero that lawmakers have no reason to take him seriously.

Sen. Jesse Bjorkman, R-Nikiski, speaks in support overriding Gov. Mike Dunleavy’s veto of House Bill 69 at the Alaska Capitol in Juneau, Alaska, on Tuesday, April 22, 2025. (Mark Sabbatini/Juneau Empire)
Capitol Corner: Finishing a session that will make a lasting impact

Sen. Jesse Bjorkman reports back from Juneau.